As we celebrate the one-year anniversary of the launch of Eversense® E3 in the U.S., Ascensia Diabetes Care, the global diabetes care company and maker of the CONTOUR® Blood Glucose Monitoring (BGM) system, has shared an update on its commercial success and outlook for future innovation.
The Eversense® Continuous Glucose Monitoring (CGM) System has been a tremendous success since its launch and Ascensia is looking forward to continuing to provide innovative solutions to people living with diabetes.
We are thrilled to have seen our partnership with Senseonics grow and develop over the past year. At Ascensia Diabetes Care, we are committed to increasing access to this groundbreaking product, while Senseonics is focused on pushing the boundaries of innovation based on patient feedback. We have an ambitious vision for the future of diabetes management and are looking forward to what lies ahead.
Ascensia has recently unveiled the cutting-edge Eversense® E3 CGM System for patients in the United States, approved by the FDA. Developed by Senseonics, this revolutionary system features the longest-lasting CGM sensor available, offering up to six months of wear, compared to just one or two weeks with most CGM systems.
Additionally, this next-generation technology boasts a fully implantable sensor, a removable smart transmitter*, discreet on-body vibe alerts, exceptional accuracy1, and an intuitive smartphone app. In the past year, this innovative system has made a significant impact on the diabetes management landscape, ensuring that people with diabetes have access to the best possible care.
U.S. COMMERCIAL HIGHLIGHTS
We’ve achieved tremendous success in getting our product covered, with over 250 million lives now enjoying access. Medicare has granted favorable reimbursement and nearly all major national insurers have added our product to their plans. This makes our product more accessible than ever before.
Since the launch of Eversense E3, we have seen a significant expansion in the number of Eversense users, setting the stage for an impressive year of growth in the US. With this increased user base, we are confident that the future of Eversense looks bright.
PASS (Payment Assistance and Simple Savings) Program is here to help Eversense users reduce out-of-pocket expenses when they have insurance coverage. This program makes it easier for them to get the medical care they need without the worry of high costs. With PASS, users can save money and obtain the care they need without breaking their budgets.
The number of certified inserters is growing rapidly, and we have recently partnered with Nurse Practitioner Group to expand our network of certified mobile and at-home inserters. This partnership will allow us to provide more comprehensive and accessible services to our clients.
We are committed to providing greater opportunity for those living with type 2 diabetes, with half of those using our system being type 2 diabetes patients. By expanding access to our resources, we are striving to ensure that those living with this condition have the support they need to live healthy and fulfilling lives.
At Eversense, we’re thrilled to welcome a growing number of new users who have made the switch from their current Continuous Glucose Monitors (CGM) to our advanced technology. With its long-lasting, accurate and easy-to-use design, Eversense is quickly becoming the go-to choice for those looking to take control of their diabetes management.
We are thrilled to share that we have been expanding our CGM salesforce to increase Eversense awareness and adoption. This dedicated team is committed to providing the best experience for our customers, and we are excited to see the impact this expansion will have.
Innovation Outlook
The Eversense 365-day sensor is on the brink of revolutionizing the medical industry, with a pivotal clinical trial underway and plans to submit data for FDA approval by mid-2024. Even more exciting, the pediatric cohort of the trial has begun enrolling and assessing the efficacy of the groundbreaking device in youth.
We are striving to bring Eversense’s iCGM clearance and integration with automated insulin delivery systems to fruition, and are working diligently to reach our goal!
The Gemini development program is pioneering an innovative approach to diabetes care, combining real-time CGM monitoring and on-demand intermittent scanning to provide patients with greater flexibility and control over managing their condition.
By giving them the opportunity to monitor their glucose levels at their own convenience, Gemini is helping to empower those living with diabetes and make life easier.
Work is underway on the revolutionary Eversense Freedom system, which promises to provide all the great features and benefits of Eversense but without the need for any on-body components. This will truly be a game-changer, allowing users to experience the same level of convenience and accuracy without the hassle of wearing a device.
Last year marked a momentous occasion for the partnership between Ascensia and Senseonics, allowing both companies to focus on their core strengths. Senseonics was able to devote its resources to research, development, innovation, and manufacturing, while Ascensia leveraged its market-leading position in BGM to lead worldwide marketing and commercialization of the Eversense product, thereby supporting patient access. This collaboration has also enabled the development of future products, furthering both organizations’ goals.